Trials / Withdrawn
WithdrawnNCT01653522
The Impact of Triptan and Doxycycline on Neuroinflammatory Biomarkers in Acute Migraine
- Status
- Withdrawn
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- The Cleveland Clinic · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to determine the effects of triptans and doxycycline on neuroinflammatory markers in acute migraine.
Detailed description
Increased inflammatory cytokines and matrix metalloproteinases (MMPs) have been recently implicated in migraine. Inflammation may be a key player in the pathophysiology of migraine by altering blood-brain barrier (BBB) function. As an inflammation induced MMP, MMP-9 is involved in both BBB disruption and neuropathic pain, and is largely derived by neutrophil degranulation during neutrophil-BBB interaction. The tetracycline group of antibiotics may suppress MMP production and neutrophil degranulation. This study aims to investigate known neuroinflammatory biomarkers with a focus on BBB breakdown during acute migraine attacks and assess marker responses to conventional treatment (triptans) and novel MMP targeted therapy (doxycycline). This pilot project data will supplement future projects investigating novel therapeutic strategies such as MMP inhibitors in both migraine acute treatment and prevention.
Conditions
- Migraine Disorders
- Headache, Migraine
- Migraine
- Migraine Headache
- Migraine With Aura
- Migraine Without Aura
- Headache Disorders, Primary
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Triptan | |
| DRUG | Doxycycline |
Timeline
- Start date
- 2012-07-01
- Primary completion
- 2014-07-01
- Completion
- 2014-07-01
- First posted
- 2012-07-31
- Last updated
- 2016-12-29
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01653522. Inclusion in this directory is not an endorsement.